AbbVie Inc. (ABBV)

AbbVie  has had a good August, with double digit MoM gains after seeing weakness for six months. Factors like an EU-US deal on pharmaceuticals, recent results, improved guidance, positive outcomes in ...

AbbVie ABBV has announced a deal with private neuroscience biotech, Gilgamesh Pharmaceuticals, to acquire the latter's lead pipeline candidate, bretisilocin (GM-2505), a novel therapy being developed ...

Q2 earnings results were strong for AbbVie as top line growth is at a historically high level and operating margin expanded due to SG&A efficiencies. The company's Rinvoq drug has new market potential...

AbbVie said on Monday it would buy privately held Gilgamesh Pharmaceuticals' treatment for major depressive disorder in a deal worth up to $1.2 billion.

Dividend Kings underperformed SPY year-to-date but are showing stronger gains in August, with several stocks achieving double-digit returns in 2025. Fifteen Dividend Kings currently appear undervalued...

Building a portfolio capable of earning strong returns over long periods is not easy, but there are some basic principles we can try to follow to simplify the task. One is to start with companies that...

AbbVie has delivered strong total returns and dividend growth over time. Additionally, it enjoys strong growth prospects. However, it also faces significant uncertainty and risks.

How does getting paid to own a stock sound to you? That's exactly what dividends do.

ABBV posts strong phase III alopecia areata data from the second study on Rinvoq. The drug hit $3.7B in H1 sales and is expected to further drive growth in H2.

AbbVie's oncology sales climbed 4.2% in H1 2025 as new drugs offset Imbruvica declines, strengthening its long-term growth outlook.